BiotechTube

Deferasirox, Vitamin D and Azacitidine

Phase 1/2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 28/100
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

MDS

Conditions

MDS

Trial Timeline

Feb 1, 2013 → Feb 1, 2019

NCT ID
NCT01718366

About Deferasirox, Vitamin D and Azacitidine

Deferasirox, Vitamin D and Azacitidine is a phase 1/2 stage product being developed by Novartis for MDS. The current trial status is unknown. This product is registered under clinical trial identifier NCT01718366. Target conditions include MDS.

What happened to similar drugs?

0 of 5 similar drugs in MDS were approved

Approved (0) Terminated (1) Active (4)
❌Roxadustat + PlaceboAstellas PharmaPhase 3
🔄Venetoclax + Azacitidine + PlaceboAbbViePhase 3
🔄Darbepoetin alfa + PlaceboAmgenPhase 3
🔄Darbepoetin AlfaAmgenPhase 3
🔄APR-246 + azacitidine + AzacitidineAprea TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01718366Phase 1/2UNKNOWN

Competing Products

20 competing products in MDS

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
Roxadustat + PlaceboAstellas PharmaPhase 3
32
KRN321Kyowa KirinPhase 2
35
Azacitidine + VenetoclaxAbbViePhase 1
33
venetoclax + azacitidineAbbViePhase 1
29
Venetoclax + Azacitidine + PlaceboAbbViePhase 3
44
venetoclax + azacitidine +/- donor lymphocyte infusionAbbViePhase 1/2
36
Birabresib Dose 20 mgMerckPhase 1
21
Azacitidine and LDE255NovartisPhase 1
29
MBG453 + Azacitidine + Decitabine + INQOVI (oral decitabine)NovartisPhase 2
27
PanobinostatNovartisPhase 2
27
Azacitidine + Azacitidine plus DeferasiroxNovartisPhase 2
27
LGH447 + LGH447 + midostaurinNovartisPhase 1
29
PanobinostatNovartisPhase 1
29
sabatolimab + azacitidine + venetoclaxNovartisPhase 2
27
LBH589 + Epoetin AlfaNovartisPhase 2
27
Placebo + RomiplostimAmgenPhase 2
35
Darbepoetin alfa + PlaceboAmgenPhase 3
40
Darbepoetin AlfaAmgenPhase 3
40